DxTerity ： 推进基因组检测的临床应用

最近，分子诊断公司开始关注一种新的基因检测技术。该技术可以避开传统检测分析所需要的RNA分离和样品准备步骤。并且，检测快速，低成本，适用于大样本的高通量分析。

DxTerity诊断公司开发了一种独一无二的的化学扩增方法：DxDirect，作为其分子诊断技术的基础。DxTerity诊断公司研发旨在疾病的监测和诊断。目前，该公司已经开发了用于炎症基因标记物的相关检测。这些检测只需要一滴血液样本，过程简单快速。

DxTerity希望基因检测技术成为临床检测的常规步骤。目前，基因检测的成本还是比较高。DxTerity的 Dx Direct平台可以允许研究者以比较低的价格对临床病人的一滴血液样本进行高通量的基因组检测。

原文： DxTerity: Bringing Genomic Testing to the Patient

Of late, molecular diagnostics companies have focused attention on developing technologies that can bypass RNA isolation and sample preparation needed for conventional PCR-based expression analysis. These technologies can also be adapted by companies and academic institutions with gene signatures requiring large validation studies because they provide rapid results at relatively low cost.

One such company, DxTerity Diagnostics, has developed unique amplification chemistry, DxDirect, as the basis of its molecular tests. DxTerity develops assays for disease monitoring and diagnosis. Thus far, the company has developed tests to detect conditions related to inflammatory genetic markers, including radiation exposure and rheumatoid arthritis using its DxDirect Genomic Analysis platform. These tests, the company says, can enable simple, fast, and affordable measurement of genomic biomarkers from a single drop of blood.

DxTerity’s goal is to make genomic testing a routine part of healthcare. Currently, costs are too high for standard use. DxTerity’s Dx Direct platform lets doctors run a wide variety of genomic tests from a single drop of blood at an affordable price.